Duvelisib
- Generic Name
- Duvelisib
- Brand Names
- Copiktra
- Drug Type
- Small Molecule
- Chemical Formula
- C22H17ClN6O
- CAS Number
- 1201438-56-3
- Unique Ingredient Identifier
- 610V23S0JI
Overview
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Background
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Indication
Duvelisib is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have trialed at least two prior therapies.
Associated Conditions
- Refractory Small Lymphocytic Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia (CLL)
- Relapsed Small Lymphocytic Lymphoma
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.